Your browser is no longer supported. Please, upgrade your browser.
Settings
OTLK Outlook Therapeutics, Inc. daily Stock Chart
OTLK [NASD]
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own8.60% Shs Outstand82.50M Perf Week11.11%
Market Cap99.00M Forward P/E- EPS next Y- Insider Trans- Shs Float15.94M Perf Month81.76%
Income-48.00M PEG- EPS next Q- Inst Own7.10% Short Float0.38% Perf Quarter71.38%
Sales3.10M P/S31.94 EPS this Y27.00% Inst Trans18.23% Short Ratio0.24 Perf Half Y54.84%
Book/sh-0.33 P/B- EPS next Y- ROA-156.30% Target Price1.50 Perf Year0.00%
Cash/sh0.00 P/C495.00 EPS next 5Y- ROE158.60% 52W Range0.21 - 1.37 Perf YTD140.00%
Dividend- P/FCF- EPS past 5Y- ROI778.50% 52W High-12.41% Beta-
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low484.23% ATR0.12
Employees56 Current Ratio0.10 Sales Q/Q37.50% Oper. Margin- RSI (14)68.69 Volatility15.41% 13.42%
OptionableNo Debt/Eq- EPS Q/Q82.30% Profit Margin- Rel Volume0.82 Prev Close1.20
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume252.87K Price1.20
Recom- SMA2032.80% SMA5066.60% SMA20042.84% Volume0 Change0.00%
Feb-14-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 GlobeNewswire +24.27%
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-01-19 09:15AM  Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement GlobeNewswire
Jan-22-19 09:00AM  Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants GlobeNewswire
Jan-02-19 09:15AM  Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement GlobeNewswire +10.00%
Dec-18-18 09:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 GlobeNewswire +14.29%
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.